Synlogic, Inc., a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced the appointment of Michael Burgess, M.B., Ch.B., Ph.D., president of research and development at Turnstone Biologics, to its board of directors.
January 30, 2020
· 5 min read